Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: Role of immune suppression

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2467-2473

  Graybill, John R ^a,b   Bocanegra, Rosie ^a   Najvar, Laura K ^a   Loebenberg, David ^c   Luther, Mike F ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUOROURACIL; HYDROCORTISONE; POSACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG MIXTURE; DRUG POTENTIATION; IMMUNE DEFICIENCY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ABSCESS; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031665183     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2467     Document Type: Article

References (41)

1. Adelman, B. A., A. Bentman, P. Rosenthal, B. R. Smith, K. R. Bridges, and W. Holmes. 1979. Treatment of aspergillosis in leukemia. Ann. Intern. Med. 91:323-324.
2. Albelda, S. M., G. H. Talbot, S. L. Gerson, W. T. Miller, and P. A. Cassileth. 1985. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis: influence of bone marrow recovery in patients with acute leukemia. Am. Rev. Respir. Dis. 131:115-120.
3. Andriole, V. T. 1993. Infections with Aspergillus species. Clin. Infect. Dis. 17(Suppl. 2):S481-S486.
4. Berenguer, J., M. C. Allende, J. W. Lee, K. Garret, C. Lyman, N. M. Ali, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1995. Pathogenesis of pulmonary aspergillosis - granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am. J. Respir. Crit. Care Med. 152:1079-1086.
5. Binder, R. E., L. J. Faling, R. D. Pugatch, C. Mahasaen, and G. L. Snider. 1982. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 61:109-124.
6. Borkin, M. H., F. P. Arena, A. E. Brown, and D. Armstrong. 1980. Invasive aspergillosis with massive fatal hemoptysis in patients with neoplastic disease. Chest 78:835-839.
7. Brown, E., S. Freedman, R. Arbeit, and S. Come. 1980. Invasive pulmonary aspergillosis in an apparently nonimmunocompromised host. Am. J. Med. 69:624-627.
8. Cohen, J., D. W. Denning, M. A. Viviani, and EORTC Invasive Fungal Infection Cooperative Group. 1993. Epidemiology of invasive aspergillosis in European cancer centres. Eur. J. Clin. Microbiol. Infect. Dis. 12:392-393.
9. Cook, D. J., M. R. Achong, and D. E. L. King. 1990. Disseminated aspergillosis in an apparently healthy patient. Am. J. Med. 88:74-76.
10. Denning, D. W., S. F. Follansbee, M. Scolaro, S. Norris, H. Edelstein, and D. A. Stevens. 1991. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324:654-662.
11. Denning, D. W., and D. A. Stevens. 1990. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12: 1147-1201.
12. deRepentigny, L., S. Petitbois, M. Boushira, E. Michaliszyn, S. Senechal, N. Gendron, and S. Montplaisir. 1993. Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect. Immun. 61:3791-3802.
13. Diamond, R. D. 1983. Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones. J. Infect. Dis. 147:160.
14. Diamond, R. D., R. Krezicki, B. Epstein, and W. Jao. 1978. Damage to hyphal forms of fungi by human leukocytes in vitro. Am. J. Pathol. 91:313-327.
15. Dornbusch, H. J., C. E. Urban, H. Pinter, G. Ginter, R. Fotter, H. Becker, T. Miorini, and C. Berghold. 1995. Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Pediatr. Hematol. Oncol. 12:577-586.
16. Edge, J. R., D. Stansfield, and D. E. Fletcher. 1971. Pulmonary aspergillosis in an unselected hospital population. Chest 59:407-413.
17. Finegold, S. M., D. Will, and J. F. Murray. 1959. Seminar on mycotic infections: aspergillosis. Am. J. Med. 27:463-482.
18. Gefter, W. B., T. R. Weingrad, D. M. Epstein, R. H. Ochs, and W. T. Miller. 1981. "Semi-invasive" pulmonary aspergillosis. Radiology 140:313-321.
19. Geller, R. B. 1996. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J. Clin. Oncol. 14:1371-1382.
20. Graybill, J., L. Najvar, R. Bocanegra, A. Fothergill, and M. Luther. 1996. Treatment of murine pulmonary aspergillosis with SCH56592 (SCH), abstr. F99, p. 116. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
21. Graybill, J. R., R. Bocanegra, and M. Luther. 1995. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 14:700-703.
22. Khoo, S. H., and D. W. Denning. 1994. Invasive aspergillosis in patients with AIDS. Clin. Infect. Dis. 19(Suppl. 1):S41-S48.
23. Lake, K. B., P. M. Browne, J. J. Van Dyke, and L. Ayers. 1983. Fatal disseminated aspergillosis in an asthmatic patient treated with corticosteroids. Chest 83:138-139.
24. Levitz, S. M., and R. D. Diamond. 1985. Mechanisms of resistance of Aspergillus fumigatus conidia to killing by neutrophils in vitro. J. Infect. Dis. 152: 33-42.
25. Liles, W. C., J. E. Huang, J. A. Van Burik, and R. A. Bowden. 1997. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J. Infect. Dis. 175: 1012-1015.
26. Massard, G., B. Lioure, J.-M. Wihlm, and G. Morand. 1993. Resection of mycotic lung sequestra after invasive aspergillosis. Ann. Thorac. Surg. 55: 563-564.
27. McCormick, W. F., S. S. Schochet, P. R. Weaver, and J. A. McCrary. 1975. Disseminated aspergillosis. Arch. Pathol. 99:353-359.
28. McWhinney, P. H. M., C. C. Kibbler, M. D. Hamon, O. P. Smith, L. Gandhi, L. A. Berger, R. K. Walesby, A. V. Hoffbrand, and H. G. Prentice. 1993. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin. Infect. Dis. 17:397-404.
29. Minamoto, G. Y., T. F. Barlam, and N. J. Vander Els. 1992. Invasive aspergillosis in patients with AIDS. Clin. Infect. Dis. 14:66-74.
30. Moreau, P., J. R. Zahar, N. Milpied, O. Baron, B. Mahé, D. Wu, P. Germaud, P. Despins, A. Y. Delajartre, and J. L. Harousseau. 1993. Localized invasive pulmonary aspergillosis in patients with neutropenia: effectiveness of surgical resection. Cancer 72:3223-3226.
31. Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinel-Ingroff, J. H. Rex, M. G. Rinaldi, C. R. Cooper, and M. R. McGinnis. 1995. Quality control guidelines for National Committee for Clinical Laboratory Standards-recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J. Clin. Microbiol. 33:1104-1107.
32. Polak-Wyss, A. 1991. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 34:205-215.
33. Roilides, E., A. Holmes, C. Blake, P. A. Pizzo, and T. J. Walsh. 1993. Impairment of neutrophil antifungal activity against hyphae of Aspergillus fumigatus in children infected with human immunodeficiency virus. J. Infect. Dis. 167:905-911.
34. Roilides, E., K. Uhlig, D. Venzon, P. A. Pizzo, and T. J. Walsh. 1993. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect. Immun. 61: 4870-4877.
35. Roilides, E., T. J. Walsh, P. Pizzo, and M. Rubin. 1991. Granulocyte colony stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J. Infect. Dis. 163:579-583.
36. Rowe, J. M., et al. 1995. A randomized, placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490) Blood 86:457-462.
37. Schaffner, A., H. Douglas, and A. Braude. 1982. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J. Clin. Invest. 69: 617-631.
38. Schaffner, A., H. Douglas, A. I. Braude, and C. E. Davis. 1983. Killing of Aspergillus spores depends on the anatomical source of the macrophage. Infect. Immun. 42:1109-1115.
39. Sidransky, H., and L. Friedman. 1959. The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis. Am. J. Pathol. 35:169-184.
40. Uchida, K., Y. Yamamoto, T. W. Klein, H. Friedman, and H. Yamaguchi. 1992. Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice. J. Med. Vet. Mycol. 30:293-300.
41. Yamamoto, Y., K. Uchida, T. W. Klein, H. Friedman, and H. Yamaguchi. 1992. Immunomodulators and fungal infections: use of antifungal drugs in combination with GCSF, p. 231-241. In H. Freidman (ed.), Microbial infections. Plenum Press, New York, N.Y.